Many Korean pharmaceutical firms want to enter glimepiride market

In coming autumn, Hadok-Aventis Pharma will face an uphill battle in trying to protect its glimepiride market from domestic competition as 33 generic items of Amaryl (glimepiride), an oral antidiabetic agent, received collective approvals from the Korea Food and Drug Administration on both June 24 and 25.

The KFDA delivered its basic position that off-patent drugs could be approved upon comp...